Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. (2017)

First Author: Alderson D
Attributed to:  CANCER: Trials with potential global reach and other challenging trials funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s1470-2045(17)30447-3

PubMed Identifier: 28784312

Publication URI: http://europepmc.org/abstract/MED/28784312

Type: Journal Article/Review

Volume: 18

Parent Publication: The Lancet. Oncology

Issue: 9

ISSN: 1470-2045